LABORATORY AND CLINICAL STUDIES ON T-3262 IN RESPIRATORY INFECTIONS
スポンサーリンク
概要
- 論文の詳細を見る
Laboratory and clinical studies on T-3262, a new pyridone-carboxylic acid derivative, were carried out and the following results were obtained.<BR>1. The antibacterial activity of T-3262 against the bacterial strains clinically isolated (<I>Haemophilus influenzae, Streptococcus pneunzoniae, Branhamella catarrhalis, Pseudomozzas aeruginosa, Staphylococcus aureus and Klebsiella pneumoniae</I>) was higher than those of pipemidic acid, norfloxacin, ofloxacin and enoxacin.<BR>2. Two patients with chronic respiratory tract infections were given 300 mg of T-3262 orally. The peak serum levels were 2. 35μg/ml and 0.58 μg/ml. The peak sputum levels were 0.85 μg/ml and 0.145 μg/ml.<BR>3. Sixteen patients with respiratory infection were treated with T-3262 at a daily dose of 600 mg. The overall efficacy rate was 87. 5%(excellent 4, good 10, poor 2). As a side effect, flushing and epigastric discomfort was observed in 1 patient and fever in 1. As an abnormal laboratory finding, a light increase of eosinophils was noted in 1 case.<BR>These results suggest that T-3262 is a useful oral antibacterial agent.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.